



BioCryst to Present at Barclays Global Healthcare Conference

February 28, 2019

RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2019 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq:BCRX) today announced that the company will present at the Barclays Global Healthcare Conference in Miami Beach, Florida on Tuesday, March 12, 2019 at 8:00 a.m. ET.

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst's website at <http://www.biocryst.com>.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs of oral drugs for rare diseases including BCX7353, an oral plasma kallikrein inhibitor for treatment of hereditary angioedema; a preclinical program with an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressive, and intravenous galidesivir, a broad-spectrum viral RNA polymerase inhibitor, as a potential treatment for Marburg virus disease and Yellow Fever, under contracts from NIAID and HHS/BARDA. RAPIVAB[®] (peramivir injection), an intravenous influenza virus neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.

BCRXW

Contact:

John Bluth

+1 919 859 7910

jbluth@biocryst.com